Muscarinic acetylcholine receptors

Current Pharmaceutical Design

Volumn 12, Issue 28, 2006, Pages 3573-3581

  Ishii, Masaru ^a   Kurachi, Yoshihisa ^b  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenylyl cyclase; G protein; G protein gated potassium channel; Gene targeting; Muscarinic acetylcholine receptor; Pharmacology; Phospholipase C

Indexed keywords

ADENYLATE CYCLASE; ATROPINE; CALCIUM ION; CARBACHOL; CEVIMELINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE; OXYBUTYNIN; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PILOCARPINE; PIRENZEPINE; POTASSIUM CHANNEL; PROTEIN KINASE C; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE; SOLIFENACIN; TOLTERODINE; UNINDEXED DRUG;

ANALGESIC ACTIVITY; BRADYCARDIA; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL MEMBRANE; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE TARGETING; GLAUCOMA; HUMAN; HYPERPOLARIZATION; INCONTINENCE; INTERNALIZATION; INTOXICATION; MUSCLE CRAMP; NONHUMAN; OVERACTIVE BLADDER; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SEIZURE; TISSUE DISTRIBUTION; XEROSTOMIA;

MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; PROTEIN CONFORMATION; RECEPTORS, MUSCARINIC;

EID: 33749440087     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778522056     Document Type: Review

References (81)

1. Löwi O. Über humorale Übertragbarkeit der Herznervenwirking. Pflügers Arch 1921; 189: 239-242.
2. Löwi O, Navaratil E. Übertragbarkeit der Herznevenwirking, X. Mittteilung. Über das Schicksal des Vagusstoffs. Pflügers Arch 1926; 214: 678-688.
3. Caulfield MP. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 1993; 58: 319-379.
4. Hulme EC, Lu ZL, Saldanha JW, Bee MS. Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 2003; 31: 29-34.
5. Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. Curr Opin Neurobiol 2005; 15: 370-378.
6. Winks JS, Hughes S, Filippov AK, Tatulian L, Abogadie FC, Brown DA, et al. Relationship between membrane phosphatidylinositol -4,5-bisphosphate and receptor-mediated inhibition of native neuronal M channels. J Neurosci 2005; 25: 3400-3413.
7. Fuster D, Moe OW, Hilgemann DW. Lipid- and mechanosensitivities of sodium/hydrogen exchangers analyzed by electrical methods. Proc Natl Acad Sci USA 2004; 101: 10482-10487.
8. + current in atrial myocytes. J Biol Chem 2001; 276: 5650-5658.
9. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem 1991; 46: 27-36.
10. van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovasc Drugs Ther 1995; 9: 159-167.
11. Marin MG, Culp DJ. Isolation and culture of submucosal gland cells. Clin Chest Med 1986; 7: 239-245.
12. Bosma MM, Bernheim L, Leibowitz MD, Pfaffinger PJ, Hille B. Modulation of M current in frog sympathetic ganglion cells. Soc Gen Physiol Ser 1990; 45: 43-59.
13. Caulfield MP, Robbins J, Higashida H, Brown DA. Postsynaptic actions of acetylcholine: the coupling of muscarinic receptor subtypes to neuronal ion channels. Prog Brain Res 1993; 98: 293-301.
14. Kurachi Y, Ishii M. Cell signal control of the G protein-gated potassium channel and its subcellular localization. J Physiol 2004; 554: 285-94.
15. Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol Rev 1998; 50: 723-60.
16. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004; 145: 59-66.
17. 3-mediated stimulation via Gβγq. J Biol Chem 1997; 272: 21317-21324.
18. Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001; 22: 409-414.
19. van Koppen CJ, Kaiser B. Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 2003; 98: 197-220.
20. Ungar VM, Hargrave PA, Baldwin JM, Schertler GF. Arrangement of rhodopsin transmembrane alpha-helices. Nature 1997: 389: 203-206.
21. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al, Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-745.
22. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90-113.
23. 1 muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. Mol Pharmacol 2000; 58: 175-184.
24. 1 muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch. J Biol Chem 2001; 276: 34098-34104.
25. Lu ZL, Curtis CAM, Jones PG, Pavia J, Hulme EC. The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. Mol Pharmacol 1997; 51: 234-241.
26. 1 receptor. Eur J Pharmacol 1995; 288: 251-257.
27. Page KM, Curtis CAM, Jones PG, Hulme EC. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Eur J Pharmacol 1995; 289: 429-437.
28. 1 muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol Pharmacol 1999; 56: 1031-1041.
29. Lu ZL, Hulme EC. The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis. J Biol Chem 1999; 274: 7309-7315.
30. Hulme EC, Lu ZL, Ward SD, Allman K, Curtis CA. The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 1999; 30: 247-260.
31. Liu J, Blin N, Conklin BR, Wess J. Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis. J Biol Chem 1996; 271: 6172-6178.
32. Kostenis E, Zeng FY, Wess J. Structure-function analysis of muscarinic receptors and their associated G proteins. Life Sci 1999; 64: 355-362.
33. Koenig JA, Edwardson JM. Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type. Mol Pharmacol 1996; 49: 351-359.
34. Moro O, Lameh J, Sadee W. Serine- and threonine-rich domain regulates internalization of muscarinic cholinergic receptors. J Biol Chem 1993; 268: 6862-6865.
35. Pals-Rylaarsdam R, Hosey MM. Two homologous phosphorylation domain differentially contributes to desensitization and internalization of the m2 muscarinic acetylcholine receptor. J Biol Chem 1997; 272: 14152-14158.
36. Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, et al. β-arrestin acts as a clathrin adapter in endocytosis of the b2-adrenergic receptor. Nature 1996; 383: 447-450.
37. Krupnick JG, Goodman OB Jr, Keen JH, Benovic JL. Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxyl terminus. J Biol Chem 1997; 272: 15011-15016.
38. Takei K, Haucke V. Clathrin-mediated endocytosis. Membrane factors pull the trigger. Trends Cell Biol 2001; 11: 385-391.
39. Claing A, Perry SJ, Achiriloiae M, Walker JKL, Albanesi JP, Lefkowitz RJ, et al. Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity. Proc Natl Acad Sci USA 2000; 97: 1119-1124.
40. Vogler O, Nolte B, Voss M, Schmidt M, Jakobs KH, Van Koppen CJ. Regulation of muscarinic acetylcholine receptor sequestration and function by β-arrestin. J Biol Chem 1999; 274: 12333-12338.
41. Mundel SJ, Benovic JL. Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells. J Biol Chem 2000; 275: 12900-12908.
42. Santani F, Penn RB, Gagnon AW, Benovic JL, Keen JH. Selective recruitment of arrestin-3 to clathrin-coated pits upon stimulation of G protein-coupled receptors. J Cell Sci 2000; 113: 2463-2470.
43. Tolbert LM, Lameh J. Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles. J Biol Chem 1996; 271: 17335-17342.
44. Roseberry AG, Hosey MM. Internalization of the M2 muscarinic acetylcholine receptor proceeds through an atypical pathway in HEK293 cells that is independent of clathrin and caveolae. J Cell Sci 2001; 114: 739-746.
45. 2-adrenergic receptors. J Biol Chem 1997; 272: 17836-17842.
46. Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
47. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996; 10: 69-90.
48. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 2004; 44: 423-50.
49. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 1997; 94: 13311-13316.
50. 1 muscarinic acetylcholine receptor. J Neurosci 2001; 21: 5239-5250.
51. 1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 15312-15317.
52. 1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-58.
53. 1 receptors. Neurosci Lett 2000; 278: 61-64.
54. Hartvig P, Gillberg PG, Gordh T Jr, Post C. Cholinergic mechanisms in pain and analgesia. Trends Pharmacol Sci 1989; 10: 75-79.
55. Widman M, Tucker S, Brase DA, Dewey WL. Cholinergic agents: antinociception without morphine type dependence in rats. Life Sci 1985; 36: 2007-2015.
56. 2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 1692-1697.
57. 2+ channels by using knockout mice. Proc Natl Acad Sci USA 1999; 96: 10899-10904.
58. 4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000; 292: 877-885.
59. 5 muscarinic acetylcholine receptors in peripheral tissue and brain. Life Sci 1993; 52: 441-448.
60. 3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410: 207-212.
61. 3 subtype. Proc Natl Acad Sci USA 2000; 97: 9579-9584.
62. 4 in carbamylcholine-induced gallbladder contractility. J Pharmacol Exp Ther 2002; 301: 643-650.
63. 4 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 10483-10488.
64. 5 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 2001; 98: 14096-14101.
65. Brown JH, Taylor P. In: Hardman JG, Limbird LE, eds., Muscarinic receptor agonists and antagonists. Goodman & Gilman's "The Pharmacological Basis of Therapeutics", The McGraw-Hill Companies 2001.
66. Pitschner HF, Schlepper M, Schulte B, Volz C, Palm D, Wellstein A. Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci 1989; (Suppl): 92-96.
67. Carmine AA, Brogden RN. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 1985; 30: 85-120.
68. Duncan G, Collison DJ. Role of the non-neural cholinergic system in the eye: A review. Life Sci 2003; 72: 2013-2019.
69. Ellis DZ, Nathanson JA, Rabe J, Sweadner KJ. Carbachol and nitric oxide inhibition of Na, K-ATPase activity in bovine ciliary processes. Invest Ophthalmol Vis Sci 2001; 42: 2625-2631.
70. Iwabuchi Y, Katagiri M, Masuhara T. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. Arch Int Pharmacol Ther 1994; 328: 315-325.
71. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001; 101: 249-263.
72. Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001; 22: 409-414.
73. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-262.
74. Nilvebrant L, Hallen B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-1136.
75. 2 antagonists for clinical use. Life Sci 1997; 60: 1053-1060.
76. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. The Dutch Tiotropium Study Group. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 1997; 55: 289-294.
77. Disse B. Antimuscarinic treatment for lung diseases. From research to clinical practice. Life Sci 2001; 68: 2557-2564.
78. 4- receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 112-122.
79. Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des 2005; 11(26): 3353-61.
80. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2004; 10(25): 3111-9.
81. Messer WS Jr. Bivalent ligands for G protein-coupled receptors. Curr Pharm Des 2004; 10(17): 2015-20.